Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
NCT06376045Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of rocatinlimab in asthma, sponsored by Amgen. Started May 2024; status: terminated.
02
Drugs
rocatinlimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06376045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376045.